Emtricitabine/tenofovir disoproxil fumarate vs Etravirine

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

HIV

Shared mechanism: HIV reverse transcriptase · full HIV pipeline

Emtricitabine/tenofovir disoproxil fumarate · Truvada

Marketed by Gilead Sciences

Approved in HIVsmall molecule combination
Partial signal

NCT00323544 · Phase 3 · completed

This was a randomized, open-label, active-controlled trial of 220 participants, comparing Truvada with Combivir. Its primary endpoint was a laboratory measure—change in hemoglobin—not a hard clinical or endoscopic outcome. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Next expected readout: December 2026 · NCT07584122 (registry estimate)

Reported efficacy

The primary endpoint for the study is a change from baseline in absolute haemoglobin at Week 24.: Primary endpoint, week 24 change from baseline in absolute hemoglobin: switching to Truvada+efavirenz vs continuing Combivir+efavirenz, mean difference +0.37 g/dL (95% CI 0.15 to 0.58 g/dL), P<0.001, favoring the switch arm. (met)

Result source: NCT00323544

Etravirine · Intelence

Marketed by Johnson & Johnson

Approved in HIVsmall molecule
Reliable signal

NCT00254046 · Phase 3 · completed

Participants were randomized and blinded to etravirine or placebo on top of background therapy. A significantly larger share of patients on etravirine achieved viral suppression than on placebo.

Reported efficacy

Evaluation of efficacy, tolerability and safety of TMC125 as part of an antiretroviral therapy containing TMC114/ritonavir and an investigator selected optimized background regimen. (24 weeks): Confirmed viral load <50 copies/mL at week 24: TMC125 (etravirine) 56% (170/304) vs placebo 39% (119/308); difference in response rates 17% (95% CI 9-25), p=0.005 (met)

Result source: NCT00254046

Results for HIV

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEmtricitabine/​tenofovir disoproxil fumarateEtravirine
HIV-1 RNA below 50 copies/mL (week 48)83.8% vs 79.9%vs Daurunavir + Ritonavir100 mg · wk 48 · n 383NCT02275780
5 other results
  • 85.2% vs 87.4% wk 48 · n 344 · Phase 3 · primary NCT01108510
  • 73.1% vs 66% 100 mg · wk 96 · n 379 · Phase 3 · secondary NCT02275780
  • 72.1% vs 74.1% wk 144 · n 344 · Phase 3 · secondary NCT01108510
  • 77.9% vs 79.3% wk 96 · n 344 · Phase 3 · secondary NCT01108510
  • 71.6% vs 79.7% wk 192 · n 74 · Phase 3 · secondary NCT01108510
56% vs 39%a+17 vs placebowk 24NCT00254046
HIV-1 RNA 50 copies/mL or more (week 48)—Not posted · NCT00323544—Not posted · NCT00255099
CD4 count, change (week 48)224.1 vs 206.7vs Daurunavir + Ritonavir100 mg · wk 96 · n 342NCT02275780
12 other results
  • 192.7 vs 185.6 100 mg · wk 48 · n 363 · Phase 3 · secondary NCT02275780
  • 310 vs 332 wk 144 · n 275 · Phase 3 · secondary NCT01108510
  • 277 vs 287 wk 96 · n 300 · Phase 3 · secondary NCT01108510
  • 291 vs 256 wk 96 · n 121 · Phase 3 · secondary NCT00089505
  • 223 vs 256 wk 96 · n 249 · Phase 3 · secondary NCT00089505
  • 213 vs 219 wk 48 · n 313 · Phase 3 · secondary NCT01108510
  • 172 vs 172 wk 48 · n 249 · Phase 3 · secondary NCT00089505
  • 350 vs 343 wk 192 · n 73 · Phase 3 · secondary NCT01108510
  • 191 vs 172 wk 48 · n 121 · Phase 3 · secondary NCT00089505
  • 158 vs 146 wk 48 · n 424 · Phase 4 · secondary NCT01380080
  • 96 vs 102 wk 24 · n 424 · Phase 4 · secondary NCT01380080
  • 8 vs 34 wk 48 · n 135 · Phase 4 · secondary NCT00724711
—Not posted · NCT00255099

HIV-1 RNA below 50 copies/mL (week 48)

Emtricitabine/​tenofovir disoproxil fumarate
83.8% vs 79.9%vs Daurunavir + Ritonavir100 mg · wk 48 · n 383NCT02275780
5 other results
  • 85.2% vs 87.4% wk 48 · n 344 · Phase 3 · primary NCT01108510
  • 73.1% vs 66% 100 mg · wk 96 · n 379 · Phase 3 · secondary NCT02275780
  • 72.1% vs 74.1% wk 144 · n 344 · Phase 3 · secondary NCT01108510
  • 77.9% vs 79.3% wk 96 · n 344 · Phase 3 · secondary NCT01108510
  • 71.6% vs 79.7% wk 192 · n 74 · Phase 3 · secondary NCT01108510
Etravirine
56% vs 39%a+17 vs placebowk 24NCT00254046

HIV-1 RNA 50 copies/mL or more (week 48)

Emtricitabine/​tenofovir disoproxil fumarate
—Not posted · NCT00323544
Etravirine
—Not posted · NCT00255099

CD4 count, change (week 48)

Emtricitabine/​tenofovir disoproxil fumarate
224.1 vs 206.7vs Daurunavir + Ritonavir100 mg · wk 96 · n 342NCT02275780
12 other results
  • 192.7 vs 185.6 100 mg · wk 48 · n 363 · Phase 3 · secondary NCT02275780
  • 310 vs 332 wk 144 · n 275 · Phase 3 · secondary NCT01108510
  • 277 vs 287 wk 96 · n 300 · Phase 3 · secondary NCT01108510
  • 291 vs 256 wk 96 · n 121 · Phase 3 · secondary NCT00089505
  • 223 vs 256 wk 96 · n 249 · Phase 3 · secondary NCT00089505
  • 213 vs 219 wk 48 · n 313 · Phase 3 · secondary NCT01108510
  • 172 vs 172 wk 48 · n 249 · Phase 3 · secondary NCT00089505
  • 350 vs 343 wk 192 · n 73 · Phase 3 · secondary NCT01108510
  • 191 vs 172 wk 48 · n 121 · Phase 3 · secondary NCT00089505
  • 158 vs 146 wk 48 · n 424 · Phase 4 · secondary NCT01380080
  • 96 vs 102 wk 24 · n 424 · Phase 4 · secondary NCT01380080
  • 8 vs 34 wk 48 · n 135 · Phase 4 · secondary NCT00724711
Etravirine
—Not posted · NCT00255099
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety

Coverage. Emtricitabine/tenofovir disoproxil fumarate: 6 of 6 rows · Etravirine: 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricEmtricitabine/​tenofovir disoproxil fumarate
Rows use multiple source trials
Etravirine
Rows use multiple source trials
CD4
absolute change · count
Maintenance
189.1 vs 163.3 Efavirenz count @ 48wk400 mg b.i.d.a,b,c
NCT00369941 · Phase 3 · registry result, not featured evidence
205.11 vs 221.39 Efavirenz count @ 48wka,b,c
NCT00903682 · Phase 2 · registry result, not featured evidence
HIV-1 RNA Less Than 400 Copies Per
event count · % of participants
Maintenance
86.1% (n=280) vs 81.9% (n=281) Efavirenz @ 48wk*400 mg b.i.d.d,a,b,c
NCT00369941 · Phase 3 · registry result, not featured evidence · converted to % from 241 Participants as posted
show 1 more dose
90% (n=280) vs 85.8% (n=281) Efavirenz @ 48wk*400 mg b.i.d.
NCT00369941 · Phase 3 · registry result, not featured evidence · converted to % from 252 Participants as posted
75.9% (n=79) vs 74.4% (n=78) Efavirenz @ 48wk*d,a,b,c
NCT00903682 · Phase 2 · registry result, not featured evidence · converted to % from 60 Number of participants as posted
show 1 more dose
81% (n=79) vs 79.5% (n=78) Efavirenz @ 48wk*
NCT00903682 · Phase 2 · registry result, not featured evidence · converted to % from 64 Number of participants as posted
Dropout rate
24.7%e
NCT00458393 · Phase 3
show 15 more results
16%Rectal Gel Lubricant + Truvada
NCT02401230 · Phase 4 · registry result, not featured evidence · combination
24%Truvada
NCT02401230 · Phase 4 · registry result, not featured evidence
20%
NCT01380080 · Phase 4 · registry result, not featured evidence
—
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
0%200/300 mg, Daily, by Mouth
NCT00960622 · Phase 4 · registry result, not featured evidence
—Truvada
NCT00960622 · Phase 4 · registry result, not featured evidence
—
NCT00323492 · Phase 4 · registry result, not featured evidence
24.2%100 mg
NCT02275780 · Phase 3 · registry result, not featured evidence
—1200 mg QD + Truvada
NCT02131233 · Phase 3 · registry result, not featured evidence · combination
79.9%
NCT01108510 · Phase 3 · registry result, not featured evidence · combination
25%
NCT01195467 · Phase 3 · registry result, not featured evidence
19.5%
NCT00625404 · Phase 3 · registry result, not featured evidence
25.5%400 mg b.i.d.
NCT00369941 · Phase 3 · registry result, not featured evidence
7.4%NVP/NVP
NCT00089505 · Phase 3 · registry result, not featured evidence
8.4%NoNVP/NVP
NCT00089505 · Phase 3 · registry result, not featured evidence
n/a: no completion milestonee
NCT00980538 · Phase 3 · registry result, not featured evidence
show 13 more results
20.3%400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
36%400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
40%300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
24.8%
NCT00665847 · Phase 2 · registry result, not featured evidence
20.3%
NCT00903682 · Phase 2 · registry result, not featured evidence
34.1%
NCT00128830 · Phase 2 · registry result, not featured evidence
5%Cohort I: Treatment Experienced, 2
NCT01504841 · Phase 1/2 · registry result, not featured evidence
16.7%Cohort II: Treatment Experienced,
NCT01504841 · Phase 1/2 · registry result, not featured evidence
—200 mg + 200 mg
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
—200 mg + 600/100 mg + 200 mg
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
17.9%
NCT00871234 · Phase 1 · registry result, not featured evidence
0%
NCT01625169 · Phase na · registry result, not featured evidence · combination
—
NCT01427504 · Phase na · registry result, not featured evidence · combination
Discontinued due to AEs
—e
NCT00458393 · Phase 3
show 15 more results
0%Rectal Gel Lubricant + Truvada
NCT02401230 · Phase 4 · registry result, not featured evidence · combination
8%Truvada
NCT02401230 · Phase 4 · registry result, not featured evidence
—
NCT01380080 · Phase 4 · registry result, not featured evidence
—
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
—200/300 mg, Daily, by Mouth
NCT00960622 · Phase 4 · registry result, not featured evidence
—Truvada
NCT00960622 · Phase 4 · registry result, not featured evidence
—
NCT00323492 · Phase 4 · registry result, not featured evidence
1.6%100 mg
NCT02275780 · Phase 3 · registry result, not featured evidence
—1200 mg QD + Truvada
NCT02131233 · Phase 3 · registry result, not featured evidence · combination
7.4%
NCT01108510 · Phase 3 · registry result, not featured evidence · combination
—
NCT01195467 · Phase 3 · registry result, not featured evidence
—
NCT00625404 · Phase 3 · registry result, not featured evidence
5%400 mg b.i.d.
NCT00369941 · Phase 3 · registry result, not featured evidence
—NVP/NVP
NCT00089505 · Phase 3 · registry result, not featured evidence
—NoNVP/NVP
NCT00089505 · Phase 3 · registry result, not featured evidence
6.7%e
NCT00980538 · Phase 3 · registry result, not featured evidence
show 13 more results
3.8%400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
4%400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
8%300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
7.9%
NCT00665847 · Phase 2 · registry result, not featured evidence
7.6%
NCT00903682 · Phase 2 · registry result, not featured evidence
4.7%
NCT00128830 · Phase 2 · registry result, not featured evidence
—Cohort I: Treatment Experienced, 2
NCT01504841 · Phase 1/2 · registry result, not featured evidence
—Cohort II: Treatment Experienced,
NCT01504841 · Phase 1/2 · registry result, not featured evidence
—200 mg + 200 mg
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
—200 mg + 600/100 mg + 200 mg
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
7.1%
NCT00871234 · Phase 1 · registry result, not featured evidence
—
NCT01625169 · Phase na · registry result, not featured evidence · combination
—
NCT01427504 · Phase na · registry result, not featured evidence · combination
Serious AEs
7.5%e
NCT00458393 · Phase 3
show 15 more results
0%Rectal Gel Lubricant + Truvada
NCT02401230 · Phase 4 · registry result, not featured evidence · combination
0%Truvada
NCT02401230 · Phase 4 · registry result, not featured evidence
20%
NCT01380080 · Phase 4 · registry result, not featured evidence
7.7%
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
—200/300 mg, Daily, by Mouth
NCT00960622 · Phase 4 · registry result, not featured evidence
0%Truvada
NCT00960622 · Phase 4 · registry result, not featured evidence
9.7%
NCT00323492 · Phase 4 · registry result, not featured evidence
11.7%100 mg
NCT02275780 · Phase 3 · registry result, not featured evidence
9.6%1200 mg QD + Truvada
NCT02131233 · Phase 3 · registry result, not featured evidence · combination
18.6%
NCT01108510 · Phase 3 · registry result, not featured evidence · combination
10%
NCT01195467 · Phase 3 · registry result, not featured evidence
3.2%
NCT00625404 · Phase 3 · registry result, not featured evidence
20.3%400 mg b.i.d.
NCT00369941 · Phase 3 · registry result, not featured evidence
7.4%NVP/NVP
NCT00089505 · Phase 3 · registry result, not featured evidence
10.4%NoNVP/NVP
NCT00089505 · Phase 3 · registry result, not featured evidence
10%e
NCT00980538 · Phase 3 · registry result, not featured evidence
show 13 more results
15.2%400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
8%400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
16%300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
5%
NCT00665847 · Phase 2 · registry result, not featured evidence
13.9%
NCT00903682 · Phase 2 · registry result, not featured evidence
21.8%
NCT00128830 · Phase 2 · registry result, not featured evidence
25%Cohort I: Treatment Experienced, 2
NCT01504841 · Phase 1/2 · registry result, not featured evidence
50%Cohort II: Treatment Experienced,
NCT01504841 · Phase 1/2 · registry result, not featured evidence
0%200 mg + 200 mg
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
0%200 mg + 600/100 mg + 200 mg
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
0%
NCT00871234 · Phase 1 · registry result, not featured evidence
0%
NCT01625169 · Phase na · registry result, not featured evidence · combination
20%
NCT01427504 · Phase na · registry result, not featured evidence · combination
Most frequent reported AEs
e
pharyngitis 20.2% (placebo 22.9%)
parasitic infection intestinal 18.8% (placebo 17.6%)
alanine aminotransferase increased 12.3% (placebo 12.6%)
NCT00458393 · Phase 3
show 13 more results
erectile dysfunction 4.8%
gastroenteritis 4.8%
headache 4.8%
NCT02401230 · Phase 4 · registry result, not featured evidence · combination
gastroenteritis 5.3%
pulmonary embolism 5.3%
anxiety 0%
NCT02401230 · Phase 4 · registry result, not featured evidence
neutrophil count decreased 38%
blood albumin decreased 35.6%
blood sodium decreased 34%
NCT01380080 · Phase 4 · registry result, not featured evidence
upper respiratory tract infection 9%
diarrhea 8.4%
cough 5.2%
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
diarrhoea 9.7%
abdominal pain 4.2%
bronchitis 4.2%
NCT00323492 · Phase 4 · registry result, not featured evidence
100 mg
diarrhoea 18.8%
upper respiratory tract infection 16.7%
headache 16.4%
NCT02275780 · Phase 3 · registry result, not featured evidence
1200 mg QD + Truvada
headache 15.8%
nausea 13.6%
diarrhoea 13.4%
NCT02131233 · Phase 3 · registry result, not featured evidence · combination
diarrhoea 22.1%
jaundice 22.1%
ocular icterus 20.1%
NCT01108510 · Phase 3 · registry result, not featured evidence · combination
bilateral arm pain 2.5%
cellulitis 2.5%
diarrhoea 2.5%
NCT01195467 · Phase 3 · registry result, not featured evidence
blood phosphorus decreased 19.4% (placebo 18.3%)
aspartate aminotransferase increased 13.1% (placebo 11.5%)
headache 13.1% (placebo 14.3%)
NCT00625404 · Phase 3 · registry result, not featured evidence
400 mg b.i.d.
nasopharyngitis 26.7%
headache 26%
diarrhoea 25.6%
NCT00369941 · Phase 3 · registry result, not featured evidence
cough 23.1%
neutrophil count decreased 23.1%
rash 23.1%
NCT00089505 · Phase 3 · registry result, not featured evidence
neutrophil count decreased 27.3%
rash 26.5%
cough 24.1%
NCT00089505 · Phase 3 · registry result, not featured evidence
e
cough 2.8%
upper respiratory tract infection 2.8%
pregnancy 2.2%
NCT00980538 · Phase 3 · registry result, not featured evidence
show 13 more results
400 mg once daily
elevated level of transaminase 11.4%
hyperbilirubinemia 7.6%
hyperlipidemia 7.6%
NCT00959894 · Phase 2 · registry result, not featured evidence
400/100 mg
cough 16%
headache 12%
influenza 12%
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
300/100 mg
cough 20%
nausea 16%
blood bilirubin increased 12%
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
upper respiratory tract infection 26.7%
diarrhoea 15.8%
cough 12.9%
NCT00665847 · Phase 2 · registry result, not featured evidence
nasopharyngitis 21.5%
headache 16.5%
diarrhoea 10.1%
NCT00903682 · Phase 2 · registry result, not featured evidence
diarrhoea 17.5%
upper respiratory tract infection 17.1%
sinusitis 11.4%
NCT00128830 · Phase 2 · registry result, not featured evidence
blood bicarbonate decreased 90%
blood sodium decreased 70%
nasal congestion 70%
NCT01504841 · Phase 1/2 · registry result, not featured evidence
cough 100%
nasal congestion 100%
rhinorrhoea 100%
NCT01504841 · Phase 1/2 · registry result, not featured evidence
200 mg + 200 mg
headache 18.8%
toothache 12.5%
diarrhoea 6.3%
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
200 mg + 600/100 mg + 200 mg
rash maculo-papular 20%
scleral hyperaemia 20%
headache 13.3%
NCT04630002 · Phase 1 · registry result, not featured evidence · combination
headache 14.3%
constipation 10.7%
diarrhea 7.1%
NCT00871234 · Phase 1 · registry result, not featured evidence
breast tenderness 66.7%
diarrhea 11.1%
headache 11.1%
NCT01625169 · Phase na · registry result, not featured evidence · combination
altered taste 64%
headache 16%
rash 16%
NCT01427504 · Phase na · registry result, not featured evidence · combination

Notes

  1. aTrial phases differ: Phase 2 versus Phase 3.
  2. bPopulation comparability has not been reviewed for both studies.
  3. cTreatment context has not been resolved for both arms.
  4. dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  5. ePopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Emtricitabine/tenofovir disoproxil fumarate

Cumulative Incidence of Death 4.8 vs 5.2 IPT Cumulative probability per 100 persons @ 24wk
absolute value · Cumulative probability per 100 persons
NCT01380080 · Phase 4 · registry result, not featured evidence
Cumulative Incidence of Disease Progression 16.6 vs 11.3 IPT Cumulative probability per 100 persons @ 96wk
absolute value · Cumulative probability per 100 persons
NCT01380080 · Phase 4 · registry result, not featured evidence
HIV Disease Progression 17.1 vs 12.5 IPT Cumulative probability per 100 persons @ 24wk
absolute value · Cumulative probability per 100 persons
NCT01380080 · Phase 4 · registry result, not featured evidence
show 1 more result
19.3 vs 15.3 IPT Cumulative probability per 100 persons @ 48wk
NCT01380080 · Phase 4 · registry result, not featured evidence
HIV-1 RNA Less Than 400 Copies 0% (n=424) vs 0.01% (n=426) IPT @ 0wk
event count · % of participants
NCT01380080 · Phase 4 · registry result, not featured evidence
show 3 more results
0.46% (n=424) vs 0.49% (n=426) IPT @ 4wk
NCT01380080 · Phase 4 · registry result, not featured evidence
0.84% (n=424) vs 0.85% (n=426) IPT @ 24wk
NCT01380080 · Phase 4 · registry result, not featured evidence
0.87% (n=424) vs 0.89% (n=426) IPT @ 48wk
NCT01380080 · Phase 4 · registry result, not featured evidence
CD4+ Cell 18 vs 19 IPT cells/uL @ 0wk
event count · cells/uL
NCT01380080 · Phase 4 · registry result, not featured evidence
show 3 more results
74 vs 76 IPT cells/uL @ 4wk
NCT01380080 · Phase 4 · registry result, not featured evidence
121 vs 121 IPT cells/uL @ 24wk
NCT01380080 · Phase 4 · registry result, not featured evidence
176 vs 172 IPT cells/uL @ 48wk
NCT01380080 · Phase 4 · registry result, not featured evidence
CD4+ 192.7 vs 185.6 Daurunavir + Ritonavir cells/uL @ 48wk100 mg
absolute change · cells/uL
NCT02275780 · Phase 3 · registry result, not featured evidence
show 13 more results
224.1 vs 206.7 Daurunavir + Ritonavir cells/uL @ 96wk100 mg
NCT02275780 · Phase 3 · registry result, not featured evidence
49 vs 54 IPT cells/uL @ 4wk
NCT01380080 · Phase 4 · registry result, not featured evidence
96 vs 102 IPT cells/uL @ 24wk
NCT01380080 · Phase 4 · registry result, not featured evidence
158 vs 146 IPT cells/uL @ 48wk
NCT01380080 · Phase 4 · registry result, not featured evidence
8 vs 34 ABC/3TC cells/uL @ 48wk
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
213 vs 219 ATV+RTV+FTC/TDF cells/uL @ 48wk
NCT01108510 · Phase 3 · registry result, not featured evidence · combination
277 vs 287 ATV+RTV+FTC/TDF cells/uL @ 96wk
NCT01108510 · Phase 3 · registry result, not featured evidence · combination
310 vs 332 ATV+RTV+FTC/TDF cells/uL @ 144wk
NCT01108510 · Phase 3 · registry result, not featured evidence · combination
350 vs 343 ATV+RTV+FTC/TDF cells/uL @ 192wk
NCT01108510 · Phase 3 · registry result, not featured evidence · combination
191 vs 201 LPV/r cells/uL @ 48wk
NCT00089505 · Phase 3 · registry result, not featured evidence
172 vs 201 LPV/r cells/uL @ 48wk
NCT00089505 · Phase 3 · registry result, not featured evidence
291 vs 278 LPV/r cells/uL @ 96wk
NCT00089505 · Phase 3 · registry result, not featured evidence
223 vs 278 LPV/r cells/uL @ 96wk
NCT00089505 · Phase 3 · registry result, not featured evidence
HIV-1 RNA LT 200 Copies 86.4% (n=154) vs 83.3% (n=156) ABC/3TC @ 48wk
responder rate · % of participants
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
show 1 more result
99.2% (n=154) vs 97.2% (n=156) ABC/3TC @ 48wk
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
HIV-1 RNA LT 50 Copies 93% (n=154) vs 91.1% (n=156) ABC/3TC @ 48wk
responder rate · % of participants
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
HIV-1 RNA LT 200 Copies 84.4% (n=154) vs 82.1% (n=156) ABC/3TC @ 48wk
responder rate · % of participants
Snapshot Responder Analysis (Virologic Success)
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
HIV-1 RNA Less Than 50 Copies 79.9% (n=154) vs 77.6% (n=156) ABC/3TC @ 48wk
responder rate · % of participants
Snapshot Responder Analysis (Virologic Success)
NCT00724711 · Phase 4 · registry result, not featured evidence · combination
Peak VO2 Change mL/Min 2.2 vs 2.8 Combivir or Trizivir kg @ 24wk200/300 mg, Daily, by Mouth
absolute change · kg
NCT00960622 · Phase 4 · registry result, not featured evidence
LDL-C -4.51 vs 9.92 Daurunavir + Ritonavir mg/dL @ 48wk100 mg
absolute change · mg/dL
Change from Baseline
NCT02275780 · Phase 3 · registry result, not featured evidence

+ 11 further endpoints in the CSV export.

Etravirine

HIV-1 RNA Less Than 50 Copies 0.87% (n=79) @ 24wk400 mg once daily
event count · % of participants
No placebo or comparator arm
NCT00959894 · Phase 2 · registry result, not featured evidence
show 2 more results
0.77% (n=79) @ 48wk400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
0.71% (n=79) @ 96wk400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
HIV-1 RNA LT 200 Copies 0.89% (n=79) @ 24wk400 mg once daily
event count · % of participants
No placebo or comparator arm
NCT00959894 · Phase 2 · registry result, not featured evidence
show 2 more results
0.82% (n=79) @ 48wk400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
0.77% (n=79) @ 96wk400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
CD4+ 156 cells/uL @ 24wk400 mg once daily
absolute change · cells/uL
No placebo or comparator arm
NCT00959894 · Phase 2 · registry result, not featured evidence
show 7 more results
163 cells/uL @ 48wk400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
224 cells/uL @ 96wk400 mg once daily
NCT00959894 · Phase 2 · registry result, not featured evidence
156 cells/uL @ 48wk
NCT00665847 · Phase 2 · registry result, not featured evidence
21.5 cells/uL @ 48wk
NCT00128830 · Phase 2 · registry result, not featured evidence
18.5 cells/uL @ 96wk
NCT00128830 · Phase 2 · registry result, not featured evidence
120 cells/uL @ 96wk
NCT00128830 · Phase 2 · registry result, not featured evidence
149.5 cells/uL @ 192wk
NCT00128830 · Phase 2 · registry result, not featured evidence
HIV-1 RNA Less Than 50 Copies 45.5% (n=22) @ 48wk400/100 mg
responder rate · % of participants
No placebo or comparator arm
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
50% (n=22) @ 48wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
CD4 46 count @ 4wk400/100 mg
absolute change · count
No placebo or comparator arm
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
show 7 more results
72 count @ 12wk400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
83 count @ 24wk400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
132 count @ 48wk400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
55 count @ 4wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
31 count @ 12wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
54 count @ 24wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
105 count @ 48wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
Virological Response 50 Copies Snapshot 45.5% (n=22) @ 48wk400/100 mg
responder rate · % of participants
No placebo or comparator arm
Virologic Response
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
50% (n=22) @ 48wk300/100 mg
Virologic Response
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
HIV-1 RNA -1.8 copies/mL @ 4wk400/100 mg
absolute change · copies/mL
No placebo or comparator arm
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
show 7 more results
-2 copies/mL @ 12wk400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
-1.8 copies/mL @ 24wk400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
-1.4 copies/mL @ 48wk400/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
-1.9 copies/mL @ 4wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
-1.7 copies/mL @ 12wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
-1.8 copies/mL @ 24wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
-1.4 copies/mL @ 48wk300/100 mg
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
Time to Viral Suppression 2.5 months400/100 mg
time to event · months
No placebo or comparator arm
Plasma VL < 50 copies/mL
NCT00896051 · Phase 2 · registry result, not featured evidence · combination · converted to months from 76 days as posted
show 1 more result
2.33 months*300/100 mg
Plasma VL < 50 copies/mL
NCT00896051 · Phase 2 · registry result, not featured evidence · combination · converted to months from 71 days as posted
Time to Virologic Failure NA months400/100 mg
time to event · months
No placebo or comparator arm
Virologic Responders (Plasma VL < 50 copies/mL)
NCT00896051 · Phase 2 · registry result, not featured evidence · combination
show 1 more result
10.45 months*300/100 mg
Virologic Responders (Plasma VL < 50 copies/mL)
NCT00896051 · Phase 2 · registry result, not featured evidence · combination · converted to months from 318 days as posted
Virologic 52.5% (n=101) @ 24wk
responder rate · % of participants
No placebo or comparator arm
NCT00665847 · Phase 2 · registry result, not featured evidence
HIV-1 RNA -1.53 log @ 48wk
absolute change · log
No placebo or comparator arm
NCT00665847 · Phase 2 · registry result, not featured evidence
HIV-1 RNA Less Than 50 Copies 58% (n=181) @ 96wk
responder rate · % of participants
No placebo or comparator arm
Viral load (VL) less than 50 copies/mL
NCT00128830 · Phase 2 · registry result, not featured evidence · converted to % from 105 Participants as posted
show 1 more result
70.4% (n=98) @ 192wk*
Viral load (VL) less than 50 copies/mL
NCT00128830 · Phase 2 · registry result, not featured evidence · converted to % from 69 Participants as posted

+ 6 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Emtricitabine/tenofovir disoproxil fumarate's landscape · Etravirine's landscape